FDA
-
-
-
-
-
-
-
Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis
-
-
-
-
-
-
-
Intrexon (XON) Subsidiary ActoBio Therapeutics Grantef IND Green Light for New Antigen-Specific Immunotherapy Study
-
-
-
-
-
-
-
Oragenics (OGEN) Announces Development Update of AG013 for Oral Mucositis
-
-
-
-
-
-
-
Fibrocell Science (FCSC) Announces Pact with Castle Creek Pharma to Develop and Commercialize FCX-007 Gene Therapy
-
-
-
-
-
-
-
Fibrocell to Host Conference Call & Webcast for Full Year 2018 Financial Results and Recent Highlights on March 27, 2019
-
-
-
-
-
-
-
Intrexon (XON) Subsidiary Precigen Announces Clearance of IND to Initiate Phase 1 Study for First-in-Class PRGN-3005 UltraCAR-T
-
-
-
-
-
-
-
Fibrocell Receives $900,000 Investment from EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

